Maze Therapeutics (NASDAQ:MAZE) Given New $37.00 Price Target at BTIG Research

Key Points

• BTIG Research has raised the price target for Maze Therapeutics from $30 to $37, indicating a potential upside of 49.19% based on the company's previous close.
• The stock has received multiple positive ratings, including a consensus rating of "Buy" from several analysts, with two analysts giving a Strong Buy rating.
• Initially, the company reported earnings of ($0.77) EPS, which was better than the consensus estimate of ($0.79), showcasing an improvement in financial performance.

Maze Therapeutics (NASDAQ:MAZE - Free Report) had its price objective boosted by BTIG Research from $30.00 to $37.00 in a research note published on Friday morning, MarketBeat Ratings reports. They currently have a buy rating on the stock.

Several other analysts have also issued reports on MAZE. Wedbush started coverage on Maze Therapeutics in a research note on Tuesday, July 8th. They issued an "outperform" rating and a $17.00 target price on the stock. HC Wainwright started coverage on Maze Therapeutics in a research note on Wednesday, July 23rd. They issued a "buy" rating and a $34.00 target price on the stock. Finally, Wall Street Zen upgraded Maze Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, August 16th. Two equities research analysts have rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. Based on data from MarketBeat.com, Maze Therapeutics presently has a consensus rating of "Buy" and an average target price of $32.67.

Maze Therapeutics Stock Up 2.4%

MAZE stock traded up $0.57 during midday trading on Friday, hitting $24.03. The company's stock had a trading volume of 129,839 shares, compared to its average volume of 262,638. The stock's 50-day moving average price is $15.67 and its 200 day moving average price is $12.43. Maze Therapeutics has a 1 year low of $6.71 and a 1 year high of $25.50.

Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.77) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.79) by $0.02.

Insiders Place Their Bets

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the company's stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $22.37, for a total value of $464,043.28. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors have recently bought and sold shares of MAZE. General Catalyst Group Management LLC purchased a new stake in Maze Therapeutics during the 1st quarter valued at about $11,405,000. Bessemer Group Inc. bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $5,305,000. Bank of New York Mellon Corp bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $190,000. New York State Common Retirement Fund bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $25,000. Finally, Alphabet Inc. bought a new position in Maze Therapeutics during the 1st quarter valued at approximately $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.